



PTO/SB/06/A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/583,280 – Conf. # 2639
				Filing Date	June 16, 2006
				First Named Inventor	Charles Sawyers
				Art Unit	1636
				Examiner Name	Nancy S. Vogel
Sheet	1	of	7	Attorney Docket Number	58086-232451

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.*	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	4,097,578	06-27-1978	Perronnet et al.	
	A2	4,399,216	08-16-1983	Axel et al.	
	A3	4,559,157	12-17-1985	Smith et al.	
	A4	4,608,392	08-26-1986	Jacquet et al.	
	A5	4,820,508	04-11-1989	Wortzman	
	A6	4,938,949	07-03-1990	Borch et al.	
	A7	4,992,478	02-12-1991	Geria	
	A8	5,010,182	04-23-1991	Brake et al.	
	A9	5,411,981	05-02-1995	Gaillard-Kelly et al.	
	A10	5,434,176	07-18-1995	Claussner et al.	
	A11	5,656,651	08-12-1997	Sovak et al.	
	A12	5,705,654	01-06-1998	Claussner et al.	
	A13	5,750,553	05-12-1998	Claussner et al.	
	A14	5,985,868	11-16-1999	Gray	
	A15	6,087,509	07-11-2000	Claussner et al.	
	A16	6,479,063	11-12-2002	Weisman et al.	
	A17	6,506,607	01-14-2003	Shyan	
	A18	2004/0009969	01-15-2004	Cleve et al.	
	A19	2002/0133833 A1	09-19-2002	Sawyers et al.	
	A20	6,828,471	12-07-04	Sawyers et al.	

Examiner Signature	Date Considered
-----------------------	--------------------

DC2/86958

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.A./

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/583,280 – Conf. # 2639
				Filing Date	June 16, 2006
				First Named Inventor	Charles Sawyers
				Art Unit	1636
				Examiner Name	Nancy S. Vogel
Sheet	2	of	7	Attorney Docket Number	58086-232451

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	B1	EP 362,179	04-04-1990	Smithkline Beecham Corporation		
	B2	WO 00/17163 (with English abstract)	03-30-2000	Yamanouchi Pharmaceutical Co., Ltd., et al.		
	B3	WO 90/13646 (with English abstract)	11-15-1990	Transgene S.A. Achstetter, et al.		
	B4	WO 97/00071	01-03-1997	Biophysica Foundation Sovak, et al.		
	B5	WO 2005/099693	10-27-2005	The Regents of the University of California		
	B6	WO 2006/124118	11-23-2006	The Regents of the University of California		
	B7	WO 2005/059109	06-30-2005	The Regents of the University of California		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				†
	C1	Karp et al., Cancer Res. 56: 5547-5556.				
	C2	Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).				
	C3	Sambrook et al., Molecular Cloning: A Laboratory Manual 2 nd edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.				
	C4	Chang et al., Science 240 (4850), 324-326 (1988).				
	C5	NM_000044< gi:21322251">http://www.ncbi.nlm.nih.gov:80/entrez/viewer.fcgi?cmd=Retrieve&db=nucleotide&list_uids=21322251&dopt=GenBank&term=sapiens+AR+androgen+recept+or+prostate+cancer&qty=1>gi:21322251 , printed October 24, 2007.				
	C6	Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991).				
	C7	Graham and van der Eb, Virology, 52:456-467.				
	C8	Keown et al., Methods in Enzymology, 185:527-537 (1990).				
	C9	Mansour et al., Nature, 336:348-352 (1988).				
	C10	Muller et al., 1991, Mol. & Cell. Bio. 11:1785.				
	C11	Urbau et al., Proc. Natl. Acad. Sci. USA, 77:4216 (1980).				
	C12	Stinchcomb et al., Nature, 282:39 (1979).				
Examiner Signature					Date Considered	

Substitute for form 1449/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>		Complete if Known	
Application Number		10/583,280 – Conf. # 2639	
Filing Date		June 16, 2006	
First Named Inventor		Charles Sawyers	
Art Unit		1636	
Examiner Name		Nancy S. Vogel	
Attorney Docket Number		58086-232451	

Sheet	3	of	7
-------	---	----	---

C13	Kingsman et al., Gene, 7: 141 (1979).	
C14	Tschumper et al., Gene, 10: 157 (1980).	
C15	Jones, Genetics, 85:12 (1977).	
C16	Feldman, B.J. & Feldman, D. The development of androgen-independent prostate cancer. Nat Rev Cancer 1, 34-45 (2001).	
C17	Gelmann, E.P. Molecular biology of the androgen receptor. J Clin Oncol 20, 3001-15 (2002).	
C18	Balk, S.P. Androgen receptor as a target in androgen-independent prostate cancer. Urology 60, 132-8; discussion 138-9 (2002).	
C19	Taplin, M.E. et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59, 2511-5 (1999).	
C20	Taplin, M.E. et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21, 2673-8 (2003).	
C21	Visakorpi, T. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9, 401-6 (1995).	
C22	Taplin, M.E. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332, 1393-8 (1995).	
C23	Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990).	
C24	Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45, 1439-46 (2002).	
C25	Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5, 280-5 (1999).	
C26	Gioeli, D. et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277, 29304-14 (2002).	
C27	Kato, S. et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270, 1491-4 (1995).	
C28	Font de Mora, J. & Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20, 5041-7 (2000).	
C29	Tremblay, A., Tremblay, G.B., Labrie, F. & Giguere, V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell 3, 513-9 (1999).	
C30	Gregory, C.W. et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61, 4315-9 (2001).	
C31	Li, P. et al. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol 161, 1467-74 (2002).	
C32	Glass, C.K. & Rosenfeld, M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14, 121-41 (2000).	

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>		Complete if Known	
		Application Number	10/583,280 – Conf. # 2639
		Filing Date	June 16, 2006
		First Named Inventor	Charles Sawyers
		Art Unit	1636
		Examiner Name	Nancy S. Vogel
		Attorney Docket Number	58086-232451

C33	Raffo, A.J. et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. <i>Cancer Res</i> 55, 4438-45 (1995).	
C34	McDonnell, T.J. et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. <i>Cancer Res</i> 52, 6940-4 (1992).	
C35	Kinoshita, H. et al. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. <i>Cancer Res</i> 60, 3623-30 (2000).	
C36	Shang, Y., Myers, M. & Brown, M. Formation of the androgen receptor transcription complex. <i>Mol Cell</i> 9, 601-10 (2002).	
C37	Zhou, H.Y. et al. Androgen-repressed phenotype in human prostate cancer. <i>Proc Natl Acad Sci U S A</i> 93, 15152-7 (1996).	
C38	Wainstein, M.A. et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. <i>Cancer Res</i> 54, 6049-52 (1994).	
C39	Ellis, W.J. et al. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. <i>Clin Cancer Res</i> 2, 1039-48 (1996).	
C40	Horoszewicz, J.S. et al. LNCaP model of human prostatic carcinoma. <i>Cancer Res</i> 43, 1809-18 (1983).	
C41	Klein, K.A. et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. <i>Nat Med</i> 3, 402-8 (1997).	
C42	Perou, C.M. et al. Molecular portraits of human breast tumors. <i>Nature</i> 406, 747-52 (2000).	
C43	Gregory, C.W., Johnson, R.T., Jr., Mohler, J.L., French, F.S. & Wilson, E.M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. <i>Cancer Res</i> 61, 2892-8. (2001).	
C44	Huang, Z.Q., Li, J. & Wong, J. AR possess an intrinsic hormone-independent transcriptional activity. <i>Mol Endocrinol</i> 16, 924-37 (2002).	
C45	Matias, P.M. et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. <i>J Biol Chem</i> 275, 26164-71 (2000).	
C46	Lobaccaro, J.M. et al. Molecular modeling and in vitro investigations of the human androgen receptor DNA-binding domain: application for the study of two mutations. <i>Mol Cell Endocrinol</i> 116, 137-47 (1995).	
C47	Migliaccio, A. et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. <i>Embo J</i> 19, 5406-17 (2000).	
C48	Kousteni, S. et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. <i>Cell</i> 104, 719-30 (2001).	
C49	Manolagas, S.C., Kousteni, S. & Jilka, R.L. Sex steroids and bone. <i>Recent Prog Horm Res</i> 57, 385-409 (2002).	

Examiner Signature	Date Considered
--------------------	-----------------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/583,280 – Conf. # 2639
				Filing Date	June 16, 2006
				First Named Inventor	Charles Sawyers
				Art Unit	1636
				Examiner Name	Nancy S. Vogel
Sheet	5	of	7	Attorney Docket Number	58086-232451

C50	DePrimo, S.E. et al. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. <i>Genome Biol</i> 3, RESEARCH0032 (2002).	
C51	Masiello, D., Cheng, S., Bubley, G.J., Lu, M.L. & Balk, S.P. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. <i>J Biol Chem</i> 277, 26321-6 (2002).	
C52	Edwards, J., Krishna, N.S., Grigor, K.M. & Bartlett, J.M. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. <i>Br J Cancer</i> 89, 552-6 (2003).	
C53	Laitinen, S., Karhu, R., Sawyers, C.L., Vessella, R.L. & Visakorpi, T. Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. <i>Genes Chromosomes Cancer</i> 35, 66-73 (2002).	
C54	Grad, J.M., Dai, J.L., Wu, S. & Burnstein, K.L. Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. <i>Mol Endocrinol</i> 13, 1896-911 (1999).	
C55	Craft, N. et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. <i>Cancer Res</i> 59, 5030-6 (1999).	
C56	Ellwood-Yen, K. et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. <i>Cancer Cell</i> 4, 223-38 (2003).	
C57	Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. <i>Cancer Cell</i> 4, 209-21 (2003).	
C58	Shiau, A.K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. <i>Cell</i> 95, 927-37 (1998).	
C59	Norris, J.D. et al. Peptide antagonists of the human estrogen receptor. <i>Science</i> 285, 744-6 (1999).	
C60	Baek, S.H. et al. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. <i>Cell</i> 110, 55-67 (2002).	
C61	Shang, Y. & Brown, M. Molecular determinants for the tissue specificity of SERMs. <i>Science</i> 295, 2465-8 (2002).	
C62	Schellhammer, P.F. et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. <i>J Urol</i> 157, 1731-5 (1997).	
C63	Sack, J.S. et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. <i>Proc Natl Acad Sci U S A</i> 98, 4904-9 (2001).	
C64	Zhou, Z.X., Sar, M., Simental, J.A., Lane, M.V. & Wilson, E.M. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. <i>J Biol Chem</i> 269, 13115-23 (1994).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/583,280 – Conf. # 2639
				Filing Date	June 16, 2006
				First Named Inventor	Charles Sawyers
				Art Unit	1636
				Examiner Name	Nancy S. Vogel
				Attorney Docket Number	58086-232451
Sheet	6	of	7		

C65	Chen, C.D., Welsbie, D.S., Tran, C., Baek, S.H., Chen, R., Vessella, R., Rosenfeld, M.G., and Sawyers, C.L., Molecular determinants of resistance to antiandrogen therapy, <i>Nat. Med.</i> , 10: 33-39, 2004.	
C66	<i>The Pharmacological Basis of Therapeutics</i> , Goodman and Gilman, eds., Macmillan Publishing Co., New York.	
C67	The Practice of Medicinal Chemistry, Camille G. Wermuth et al., Ch 31, (Academic Press, 1996).	
C68	<i>Design of Prodrugs</i> , edited by H. Bundgaard, (Elsevier, 1985).	
C69	A Textbook of Drug Design and Development, P. Krogsgaard-Larson and H. Bundgaard, eds. Ch 5, pgs 113-191 (Harwood Academic Publishers, 1991).	
C70	Remington: The Science and Practice of Pharmacy, 19 th Edition, Gennaro (ed.) 1995, Mack Publishing Company, Easton, PA.	
C71	Teutsch, G.; Goubet, F.; Battmann, T.; Bonfils, A.; Bouchoux, F.; Ceredo, E.; Goffo, D.; Gaillard-Kelly, M.; Philibert, D. <i>J. Steroid Biochem. Molec. Biol.</i> 1994, 48, 111-119.	
C72	Van Dort, M. E.; Robins, D. M.; Wayburn, B. <i>J. Med. Chem.</i> 2000, 43, 3344-3347.	
C73	Homma, S., et al., "Differential levels of human leukocyte antigen-class I, multidrug-resistance 1 and androgen receptor expressions in untreated prostate cancer cells: the robustness of prostate cancer", <i>Oncol. Rep.</i> 18 (2), 343-346 (2007).	
C74	Cai, C., et al., "c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer", <i>Mol. Cancer Res.</i> 5 (7), 725-735 (2007).	
C75	Su, Q.R., et al., "Polymorphisms of androgen receptor gene in childhood and adolescent males with first-onset major depressive disorder and association with related symptomatology", <i>Int. J. Neurosci.</i> 117 (7), 903-917 (2007).	
C76	Brockschmidt, F.F., et al., "The two most common alleles of the coding GGN repeat in the androgen receptor gene cause differences in protein function", <i>J. Mol. Endocrinol.</i> 39 (1), 1-8 (2007).	
C77	Hamilton-Reeves, J.M., et al., "Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-beta expression or serum hormonal profiles in men at high risk of prostate cancer", <i>J. Nutr.</i> 137 (7), 1769-1775 (2007).	
C78	Sweet, C.R., et al., "A unique point mutation in the androgen receptor gene in a family with complete androgen insensitivity syndrome", <i>Fertil. Steril.</i> 58 (4), 703-707 (1992).	
C79	Batch, J.A., et al., "Androgen receptor gene mutations identified by SSCP in fourteen subjects with androgen insensitivity syndrome", <i>Hum. Mol. Genet.</i> 1 (7), 497-503 (1992).	
C80	Wooster, R., et al., "A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome", <i>Nat. Genet.</i> 2 (2), 132-134 (1992).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/583,280 – Conf. # 2639		
		Filing Date	June 16, 2006		
		First Named Inventor	Charles Sawyers		
		Art Unit	1636		
		Examiner Name	Nancy S. Vogel		
Sheet	7	of	7	Attorney Docket Number	58086-232451

C81	Saunders, P.T., et al., "Point mutations detected in the androgen receptor gene of three men with partial androgen insensitivity syndrome", Clin. Endocrinol. (Oxf) 37 (3), 214-220 (1992).	
C82	Zoppi, S., et al. "Amino acid substitutions in the DNA-binding domain of the human androgen receptor are a frequent cause of receptor-binding positive androgen resistance", Mol. Endocrinol. 6 (3), 409-415 (1992).	
C83	International Search Report issued in PCT Application PCT/US2006/011417, mailed on July 3, 2006.	
C84	International Search Report issued in PCT Application PCT/US2005/005529, mailed on November 10, 2005.	
C85	International Search Report issued in PCT Application PCT/US2004/042221, mailed on June 20, 2005.	
C86	Wang, Long G., et al., "Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line", Cancer Research 61 (20), pp. 7544-7551 (October 15, 2001).	
C87	Shi, Xu-Bao, et al., "Functional analysis of 44 mutant androgen receptors from human prostate cancer", Cancer Research 62 (5), pp. 1496-1502 (March 1, 2002).	
C88	Navone, N. M., et al., "Model Systems of Prostate Cancer: Uses and Limitations" Cancer Metastasis, Kluwer Academic Publishers, Dordrecht, NL, 17 (4), 1999, pp. 361-371.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Sean Aeder/ (08/10/2009)	Date Considered	
-----------------------	---------------------------	--------------------	--